Although investor sentiment continues to remain low and unlikely to change for the remainder of the year, it seems that fact has fallen on deaf ears of those companies looking to graduate to the public ranks. Already in the first few days of September, five biopharma companies have added themselves to the IPO runway, bringing the number of pending U.S. offerings to 12, according to BioWorld.
Although investor sentiment continues to remain low and unlikely to change for the remainder of the year, it seems that fact has fallen on deaf ears of those companies looking to graduate to the public ranks. Already in the first few days of September, five biopharma companies have added themselves to the IPO runway, bringing the number of pending U.S. offerings to 12, according to BioWorld.
PERTH, Australia – There is pervasive use of artificial intelligence and machine learning (AI/ML) across the health care industry in Australia, and excitement is building on the opportunities it offers to technologies and ultimately to patients, Ausbiotech CEO Lorraine Chiroiu told BioWorld Asia.
Two recent deals signaled to the industry that efforts to target previously undruggable RNA with small-molecule therapies may be moving from academic endeavor to fruitful application.
The turbulent financial markets that have seen the Dow Jones Industrial Average drop over 2% in August appear to have caught up with innovative mid-cap public companies engaged in exciting cancer research such as immuno-oncology. Up until now they have enjoyed strong investor support, but for the first time this year investors appear to be moving out of this sector and, as a result, share values have dipped dramatically. As a result, the BioWorld Cancer Index is trading down 11% in August.
Artificial intelligence (AI) has helped the med-tech industry in numerous ways. From genomics, to screening, to diagnostics, AI has made things easier for clinicians.
And that has caught the eye of investors. According to Mercom Capital Group LLC, as a whole, digital health venture capital funding in the second quarter 2019 jumped from the previous quarter ($3.1 billion raised in 169 deals vs. $2 billion raised in 149 deals).
The turbulent financial markets that have seen the Dow Jones Industrial Average drop over 2% so far this month appear to have caught up with innovative mid-cap public companies engaged in exciting cancer research such as immuno-oncology. Up until now they have enjoyed strong investor support, but for the first time this year investors appear to be moving out of this sector and, as a result, share values have dipped dramatically. As a result, the BioWorld Cancer Index is trading down 11% in August.
The costs associated with navigating a new therapeutic through the regulatory process to final approval and subsequent marketing continue to rise despite industry's collective efforts to speed up the process of drug discovery and development in order to rein in those burgeoning expenses.
According to a new report from the Alliance for Regenerative Medicine, there are a whopping 932 regenerative medicine companies worldwide that are in the process of developing 440 gene therapies, 587 cell therapies and 125 tissue engineering/biomaterials products.
It appeared that investors were far more interested in their vacations than in tracking the progress of blue-chip biopharma companies last month. Not helping their cause was the ongoing drug pricing debate taking place in Washington. The quest to reduce the cost of drugs moved a step closer with the Senate Finance Committee completing its markup of the Prescription Drug Pricing Reduction Act and voting 19-9 to send the legislation to the full U.S. Senate.
RSS
